Facial infiltrating lipomatosis

Last updated
Facial infiltrating lipomatosis
Other namesCongenital infiltrating lipomatosis of the face
Wilma Westenberg.jpg
Dutch blogger and YouTuber Wilma Westenberg  [ nl ] suffers from FIL
Causesgenetic mutation of the PIK3CA gene

Facial infiltrating lipomatosis (FIL), also referred to as congenital infiltrating lipomatosis of the face or facial infused lipomatosis , is an ultra-rare craniofacial overgrowth condition caused by a genetic mutation of the PIK3CA gene. [1] The condition is a part of the PIK3CA related overgrowth spectrum (PROS). [2] The disease is congenital and non-hereditary. First described by Slavin and colleagues in 1983. [3]

Contents

For this disease the mutation causes overgrowth of half of the face (hemifacial). It affects both soft and hard tissue (facial skeleton). The condition is noticeable at birth by the asymmetrical cheeks, with one cheek being prominently larger than the other. [4]

Signs & symptoms

Congenital hemifacial enlargement in which mature lipocytes invade adjacent tissue. Phenotypic features include soft-tissue and skeletal hypertrophy and regional macrodontia. The manifestations are variable ranging from mild to severe. The overgrowth is typically present at birth. The most common features, all features on only one affected side of the face, are: [5] [4]

Not all patients with facial infiltrating lipomatosis have all these symptoms.

Cause

Mutations in the PIK3CA gene have been identified as the cause for facial infiltrating lipomatosis. [6] [4] The mutation is de novo and mosaic meaning it's new, not inherited and not occurring in every cell. One of the DNA nucleotides was altered, causing a change in the amino acid put being into the protein, referred to as a missense mutation, and for PROS, this gives an overactivity, "gain-of-function". The gene is a part of PI3K-AKT/mTOR pathway, a pathway crucial to cell growth, survival, angiogenesis and proliferation.[ citation needed ]

Illustration of the PIK3CA Related Overgrowth Spectrum PIK3CA Related Overgrowth Spectrum.jpg
Illustration of the PIK3CA Related Overgrowth Spectrum

Treatment

There is no cure for FIL/PROS. Management usually consists of multiple debulking surgeries and/or drug treatment. Due to the infiltrating fat in important facial structures complete excision of the overgrowth is often impossible and there is a high risk of regrowth after resection. [4]

The current drug treatment options are either a mTOR inhibitor, a pan AKT (AKT1-2-3) inhibitor or a PIK3CA inhibitor. The mTOR inhibitor is an off-label use, the use of the AKT-inhibitor is currently in a clinical trial [7] (MOSAIC) and the PIK3CA inhibitor is only available through compassionate use program [8] (if one is eligible).

Related Research Articles

Melanocytic nevus Medical condition

A melanocytic nevus is a type of melanocytic tumor that contains nevus cells. Some sources equate the term mole with "melanocytic nevus", but there are also sources that equate the term mole with any nevus form.

Megalencephaly Medical condition

Megalencephaly is a growth development disorder in which the brain is abnormally large. It is characterized by a brain with an average weight that is 2.5 standard deviations above the mean of the general population. Approximately 1 out of 50 children (2%) are said to have the characteristics of megalencephaly in the general population.

Proteus syndrome human disease characterized by an overgrowth of skin, bones, muscles, fatty tissues, and blood and lymphatic vessels

Proteus syndrome is a rare disorder with a genetic background that can cause tissue overgrowth involving all three embryonic lineages. Patients with Proteus syndrome tend to have an increased risk of embryonic tumor development. The clinical and radiographic symptoms of Proteus syndrome are highly variable, as are its orthopedic manifestations.

Beckwith–Wiedemann syndrome Genetic overgrowth disorder

Beckwith–Wiedemann syndrome is an overgrowth disorder usually present at birth, characterized by an increased risk of childhood cancer and certain congenital features. A minority (<15%) cases of BWS are familial, meaning that a close relative may also have BWS, and parents of an affected child may be at increased risk of having other children with BWS. While children with BWS are at increased risk of childhood cancer, most children with BWS do not develop cancer and the vast majority of children who do develop cancer can be treated successfully.

Treacher Collins syndrome Human genetic disorder

Treacher Collins syndrome (TCS) is a genetic disorder characterized by deformities of the ears, eyes, cheekbones, and chin. The degree to which a person is affected, however, may vary from mild to severe. Complications may include breathing problems, problems seeing, cleft palate, and hearing loss. Those affected generally have normal intelligence.

Microtia Medical condition

Microtia is a congenital deformity where the pinna is underdeveloped. A completely undeveloped pinna is referred to as anotia. Because microtia and anotia have the same origin, it can be referred to as microtia-anotia. Microtia can be unilateral or bilateral. Microtia occurs in 1 out of about 8,000–10,000 births. In unilateral microtia, the right ear is most commonly affected. It may occur as a complication of taking Accutane (isotretinoin) during pregnancy.

Congenital melanocytic nevus Congenital mole caused by genetic mutations

The congenital melanocytic nevus is a type of melanocytic nevus found in infants at birth. This type of birthmark occurs in an estimated 1% of infants worldwide; it is located in the area of the head and neck 15% of the time.

P110α Human protein-coding gene

The phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha, also called p110α protein, is a class I PI 3-kinase catalytic subunit. The human p110α protein is encoded by the PIK3CA gene.

Monosomy 9p is a rare chromosomal disorder in which some DNA is missing or has been deleted on the short arm region, “p”, of one of the 9th Chromosomes (9p22.2-p23). This deletion either happens de novo or a result of a parent having the chromosome abnormality. This rare chromosome abnormality is often diagnosed after birth when development delay, irregular facial features, and structural irregularities within the heart, and genital defects are noticed. Treatments for this syndrome usually focus on fixing the common malformations associated with this syndrome. Chromosome 9p deletion syndrome was first discovered in 1973 when 3 infants with similar clinical features were observed to have a partial deletion of the short arm of Chromosome 9. Symptoms include microgenitalia, intellectual disability with microcephaly and dysmorphic features.

Parry–Romberg syndrome Rare disease involving degeneration of tissues beneath the skin

Parry–Romberg syndrome (PRS) is a rare disease characterized by progressive shrinkage and degeneration of the tissues beneath the skin, usually on only one side of the face but occasionally extending to other parts of the body. An autoimmune mechanism is suspected, and the syndrome may be a variant of localized scleroderma, but the precise cause and pathogenesis of this acquired disorder remains unknown. It has been reported in the literature as a possible consequence of sympathectomy. The syndrome has a higher prevalence in females and typically appears between 5 and 15 years of age.

Macrostomia refers to a mouth that is unusually wide. The term is from the Greek prefix makro- meaning "large" and from Greek στόμα, "mouth".

PI3K/AKT/mTOR pathway Cell cycle regulation pathway

The PI3K/AKT/mTOR pathway is an intracellular signaling pathway important in regulating the cell cycle. Therefore, it is directly related to cellular quiescence, proliferation, cancer, and longevity. PI3K activation phosphorylates and activates AKT, localizing it in the plasma membrane. AKT can have a number of downstream effects such as activating CREB, inhibiting p27, localizing FOXO in the cytoplasm, activating PtdIns-3ps, and activating mTOR which can affect transcription of p70 or 4EBP1. There are many known factors that enhance the PI3K/AKT pathway including EGF, shh, IGF-1, insulin, and CaM. Both leptin and insulin recruit PI3K signalling for metabolic regulation. The pathway is antagonized by various factors including PTEN, GSK3B, and HB9.

A vascular anomaly is any of a range of lesions from a simple birthmark to a large tumor that may be disfiguring. They are caused by a disorder of the vascular system. A vascular anomaly is a localized defect in blood or lymph vessels. These defects are characterized by an increased number of vessels, and vessels that are both enlarged and sinuous. Some vascular anomalies are congenital, others appear within weeks to years after birth, and others are acquired by trauma or during pregnancy. Inherited vascular anomalies are also described and often present with a number of lesions that increase with age. Vascular anomalies can also be a part of a syndrome.

Macrocephaly-capillary malformation Medical condition

Macrocephaly-capillary malformation (M-CM) is a multiple malformation syndrome causing abnormal body and head overgrowth and cutaneous, vascular, neurologic, and limb abnormalities. Though not every patient has all features, commonly found signs include macrocephaly, congenital macrosomia, extensive cutaneous capillary malformation, body asymmetry, polydactyly or syndactyly of the hands and feet, lax joints, doughy skin, variable developmental delay and other neurologic problems such as seizures and low muscle tone.

A facial cleft is an opening or gap in the face, or a malformation of a part of the face. Facial clefts is a collective term for all sorts of clefts. All structures like bone, soft tissue, skin etc. can be affected. Facial clefts are extremely rare congenital anomalies. There are many variations of a type of clefting and classifications are needed to describe and classify all types of clefting. Facial clefts hardly ever occur isolated; most of the time there is an overlap of adjacent facial clefts.

The American Society of Maxillofacial Surgeons (ASMS) is a professional organization focused on the science and practice of surgery of the facial region and craniofacial skeleton. The organization is involved in education, research, and advocacy on behalf of patients and maxillofacial surgeons.

Fibro-adipose vascular anomaly, also known as FAVA, is a type of vascular anomaly that is both rare and painful. FAVA is characterized by tough fibrofatty tissue taking over portions of muscle, most often contained within a single limb. FAVA also causes venous and/or lymphatic abnormalities.

CLOVES syndrome Medical condition

CLOVES syndrome is an extremely rare overgrowth syndrome with complex vascular anomalies. CLOVES syndrome affects people with various symptoms, ranging from mild fatty soft-tissue tumors to vascular malformations encompassing the spine or internal organs. CLOVES syndrome is closely linked to other overgrowth disorders like proteus syndrome, Klippel–Trénaunay syndrome, Sturge–Weber syndrome, and hemihypertrophy, to name a few. It can also cause fat to move to the back, and many cases undescended testicles.

PIK3CA-related overgrowth spectrum (PROS) is an umbrella term for rare syndromes characterized by malformations and tissue overgrowth caused by somatic mutations in PIK3CA gene. In PROS diseases individuals malformations are seen in several different tissues such as skin, vasculature, bones, fat and brain tissue depending on the specific disease.

Diffuse capillary malformation with overgrowth (DCMO) is a subset of capillary malformations (CM) associated with hypertrophy, i.e. increased size of body structures. CM can be considered an umbrella term for various vascular anomalies caused by increased diameter or number of capillary blood vessels. It is commonly referred to as “port-wine stain”, and is thought to affect approximately 0.5% of the population. Typically capillaries in the papillary dermis are involved, and this gives rise to pink or violaceous colored lesions. Majority of DCMO lesions are diffuse, reticulated pale-colored stains.

References

  1. Maclellan, Reid A.; Luks, Valerie L.; Vivero, Matthew P.; Mulliken, John B.; Zurakowski, David; Padwa, Bonnie L.; Warman, Matthew L.; Greene, Arin K.; Kurek, Kyle C. (January 2014). "PIK3CA Activating Mutations in Facial Infiltrating Lipomatosis". Plastic and Reconstructive Surgery. 133 (1): 12e–19e. doi:10.1097/01.prs.0000436822.26709.7c. PMID   24374682. S2CID   23828181.
  2. Keppler-Noreuil, Kim M.; Rios, Jonathan J.; Parker, Victoria E.R.; Semple, Robert K.; Lindhurst, Marjorie J.; Sapp, Julie C.; Alomari, Ahmad; Ezaki, Marybeth; Dobyns, William; Biesecker, Leslie G. (February 2015). "PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation". American Journal of Medical Genetics Part A. 167 (2): 287–295. doi:10.1002/ajmg.a.36836. PMC   4480633 . PMID   25557259.
  3. Slavin, Sumner A.; Baker, Daniel C.; McCarthy, Joseph G.; Mufarrij, Amjad (August 1983). "Congenital Infiltrating Lipomatosis of the Face". Plastic and Reconstructive Surgery. 72 (2): 158–164. doi:10.1097/00006534-198308000-00006. PMID   6192455. S2CID   28264156.
  4. 1 2 3 4 Li, Yatong; Chang, Guojing; Si, Loubin; Zhang, Hailin; Chang, Xiaoyan; Chen, Zhixiong; Huang, Jiuzuo; Bai, Ming; Wang, Yang; Long, Xiao; Zhao, Ru; Wang, Xiaojun (2018). "Congenital Infiltrating Lipomatosis of the Face". Annals of Plastic Surgery. 80 (1): 83–89. doi:10.1097/SAP.0000000000001213. PMC   5737463 . PMID   28846548.
  5. Shenoy, Archana R.; Nair, Keerthi K.; Lingappa, Ashok; Shetty, K. Sadashiva (1 April 2015). "Congenital infiltrating lipomatosis of face: Case report and review of literature". Journal of Indian Society of Pedodontics and Preventive Dentistry. 33 (2): 156–60. doi: 10.4103/0970-4388.155134 . PMID   25872637.
  6. Couto, Javier A.; Vivero, Matthew P.; Upton, Joseph; Padwa, Bonnie L.; Warman, Matthew L.; Mulliken, John B.; Greene, Arin K. (October 2015). "Facial Infiltrating Lipomatosis Contains Somatic PIK3CA Mutations in Multiple Tissues". Plastic and Reconstructive Surgery. 136: 72–73. doi:10.1097/01.prs.0000472371.96995.e5.
  7. Clinical trial number NCT03094832 for "Study of ARQ 092 in Subjects With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (MOSAIC)" at ClinicalTrials.gov
  8. Clinical trial number NCT04085653 for "Managed Access Program (MAP) to Provide Alpelisib (BYL719) for Patients With PIK3CA-Related Overgrowth Spectrum (PROS)" at ClinicalTrials.gov